{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:47:17Z","timestamp":1761176837212,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.tracli.2013.05.002","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T21:32:36Z","timestamp":1375738356000},"page":"405-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD"],"prefix":"10.1016","volume":"20","author":[{"given":"S.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2013.05.002_bib0005","unstructured":"NCJDRSU. www.cjd.ed.ac.uk [Accessed 04\/12\/2012]."},{"key":"10.1016\/j.tracli.2013.05.002_bib0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2013.05.002_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2006.00833.x","article-title":"Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study","volume":"91","author":"Hewitt","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2013.05.002_bib0020","unstructured":"ACDP. www.dh.gov.uk\/health\/about-us\/public-bodies-2\/advisory-bodies\/acdp\/in [Accessed 04\/12\/2012]."},{"key":"10.1016\/j.tracli.2013.05.002_bib0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/path.1580","article-title":"Prevalence of lymphoreticular prion protein accumulation in UK tissue samples","volume":"203","author":"Hilton","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.tracli.2013.05.002_bib0030","unstructured":"Advisory Committee on Dangerous Pathogens TSE Risk Assessment Sub Group. Position Statement on occurrence of vCJD and prevalence of infection in the UK population; https:\/\/www.wp.dh.gov.uk\/transparency\/files\/2012\/08\/ACDP-statement-vCJD-occurrence-and-prevalence-Jul-2012.pdf [Accessed 04\/12\/2012]."},{"key":"10.1016\/j.tracli.2013.05.002_bib0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2013.05.002_bib0040","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1537-2995.1998.38998408999.x","article-title":"The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy","volume":"38","author":"Brown","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2013.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.0041-1132.2003.00586.x","article-title":"Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy","volume":"43","author":"Cervenakova","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2013.05.002_bib0050","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1111\/j.1537-2995.2011.03199.x","article-title":"Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood","volume":"51","author":"Gregori","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2013.05.002_bib0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","article-title":"Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient","volume":"364","author":"Peden","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2013.05.002_bib0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2516.2009.02181.x","article-title":"Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia","volume":"16","author":"Peden","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2013.05.002_bib0065","doi-asserted-by":"crossref","first-page":"e15626","DOI":"10.1371\/journal.pone.0015626","article-title":"Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK","volume":"5","author":"Garske","year":"2010","journal-title":"PLoS One"},{"author":"Advisory Committee on Dangerous Pathogens TSE Risk Assessment Sub Group","key":"10.1016\/j.tracli.2013.05.002_bib0070"},{"key":"10.1016\/j.tracli.2013.05.002_bib0075","doi-asserted-by":"crossref","first-page":"e23169","DOI":"10.1371\/journal.pone.0023169","article-title":"All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD","volume":"6","author":"McCutcheon","year":"2011","journal-title":"PLoS One"},{"author":"European Parliament Council","key":"10.1016\/j.tracli.2013.05.002_bib0080"},{"author":"The European Commission","key":"10.1016\/j.tracli.2013.05.002_bib0085"},{"key":"10.1016\/j.tracli.2013.05.002_bib0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1423-0410.2006.00765.x","article-title":"Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates","volume":"90","author":"Sowemimo-Coker","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2013.05.002_bib0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1423-0410.2009.01206.x","article-title":"Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent\/detergent (S\/D)-treated plasma OctaplasLG","volume":"97","author":"Neisser-Svae","year":"2009","journal-title":"Vox Sang"},{"author":"Joint UKBTS\/NIBSC Professional Advisory Committee","key":"10.1016\/j.tracli.2013.05.002_bib0100"},{"key":"10.1016\/j.tracli.2013.05.002_bib0105","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.12188","article-title":"Reducing the risk of vCJD transmission - a safety trial of prion-filtered versus standard red cells transfusion in surgical patients (PRISM)","volume":"160","author":"Elebute","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2013.05.002_bib0110","unstructured":"CJD Resource Centre Oversight Committee. Evaluation of potential tests for CJD for access to rare samples (such as plasma) from vCJD patients; www.nibsc.ac.uk\/spotlight\/cjd_resource_centre\/cjd_tests.aspx Accessed 14\/12\/2012."}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782013004813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782013004813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:34:16Z","timestamp":1761129256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782013004813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1246782013004813"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2013.05.002","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2013.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}